Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724334 · ClinicalTrials.gov registry record · Phase 1
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00724334 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 42 participants.
The verdict
NCT00724334, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Interventions
- DRUG SAR302503 (TG101348)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724334
The ClinicalTrials.gov registry entry for NCT00724334 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR302503 (TG101348) is the first listed.
NCT00724334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724334 about?
NCT00724334 is a clinical study titled "A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis". The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
What is the current status of trial NCT00724334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2008-07. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00724334?
The interventions under investigation include: SAR302503 (TG101348) (DRUG).
Who is sponsoring clinical trial NCT00724334?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.